Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study

Jean-François Korobelnik , Michael Larsen , Nicole Eter , Clare Bailey , Sebastian Wolf , Thomas Schmelter , Helmut Allmeier , Varun Chaudhary

PII: S0002-9394(21)00058-1
DOI: https://doi.org/10.1016/j.ajo.2021.01.027
Reference: AJOPHT 11716

To appear in: *American Journal of Ophthalmology*

Received date: November 25, 2020
Revised date: January 27, 2021
Accepted date: January 28, 2021

Please cite this article as: Jean-François Korobelnik , Michael Larsen , Nicole Eter , Clare Bailey , Sebastian Wolf , Thomas Schmelter , Helmut Allmeier , Varun Chaudhary , Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study, *American Journal of Ophthalmology* (2021), doi: https://doi.org/10.1016/j.ajo.2021.01.027

Highlights

- From baseline to Week 76, 65.6% of patients gained ≥15 letters
- In the T&E phase, 45.0% of patients achieved a mean treatment interval of ≥8 weeks
- A last actual treatment interval of ≥8 weeks was achieved by 63.1% of patients
- Mean BCVA was 51.9 letters at baseline and 72.3 letters at Week 76 (+20.3 letters)
- Mean CRT decreased from 759.9 µm at baseline to 265.4 µm at Week 76 (−496.1 µm)

CENTERA Primary Manuscript

Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend for Macular Edema in Central Retinal Vein Occlusion: The CENTERA Study

Short title: IVT-AFL T&E for Macular Edema in CRVO

Authors

Jean-François Korobelnik,[1,2] Michael Larsen,[3] Nicole Eter,[4] Clare Bailey,[5] Sebastian Wolf,[6] Thomas Schmelter,[7] Helmut Allmeier,[8] Varun Chaudhary[9]

Affiliations:

1. CHU Bordeaux, Service d'Ophtalmologie, France
2. Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, F-33000 Bordeaux, France
3. University of Copenhagen and Department of Ophthalmology, Rigshospitalet, Copenhagen, Denmark
4. Department of Ophthalmology, University of Muenster Medical Center, Muenster, Germany
5. Bristol Eye Hospital, Bristol, UK
6. Department for Ophthalmology, Inselspital, University Hospital, University of Bern, Bern, Switzerland
7. Bayer AG, Berlin, Germany
8. Bayer Consumer Care, AG, Basel, Switzerland
9. Hamilton Regional Eye Institute; St. Joseph's Healthcare Hamilton and Department of Surgery, McMaster University, ON, Canada

Corresponding author

Professor Jean-François Korobelnik
Hôpital Pellegrin, CHU de Bordeaux, Place Amélie Raba Léon, 33000 Bordeaux, France
Tel: +33 (0)5 57 82 12 17; Fax: +33 (0)5 56 79 47 58
Email: jean-francois.korobelnik@chu-bordeaux.fr

Supplemental material available at AJO.com.

Abstract (232/250 words)

Purpose: To evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) treat-and-extend (T&E) dosing in patients with macular edema secondary to central retinal vein occlusion (CRVO).

Design: CENTERA was an open-label, Phase 4 clinical study.

Methods: Patients received 2mg IVT-AFL at baseline and every 4 weeks (wks) until disease stability criteria were met (or until Wk20), at which point treatment intervals were adjusted in 2-wk increments based on functional and anatomic outcomes.

Results: From baseline to Wk76, 65.6% (n=105; *P*<0.0001 [test against threshold of 40%]) of patients gained ≥15 letters; and, during the T&E phase, 45.0% (n=72; *P*=0.8822 [test against threshold of 50%]) of patients achieved a mean treatment interval ≥8 wks. A last and next planned treatment interval of ≥8 wks was achieved by 63.1% (n=101) and 67.5% (n=108) of patients, respectively. Mean (standard deviation) best-corrected visual acuity increased from 51.9 (16.8) letters at baseline to 72.3 (18.5) letters at Wk76 (mean change: +20.3 [19.5] letters), and central retinal thickness decreased from 759.9 (246.0) µm at baseline to 265.4 (57.9) µm at Wk76 (mean change: −496.1 [252.4] µm). The safety profile of IVT-AFL was consistent with previous studies.

Conclusions: Clinically meaningful improvements in functional and anatomic outcomes were achieved with IVT-AFL T&E dosing. Most patients achieved a last actual and last intended treatment interval of ≥8 wks, therefore treatment intervals may have been extended even further with a longer study duration.

Introduction

Retinal vein occlusion is a common cause of vision loss in patients with chronic macular edema.[1] There are three different types of retinal vein occlusion, based on obstruction site: branch retinal vein occlusion, central retinal vein occlusion (CRVO), and hemi-retinal vein occlusion.[2] CRVO is an obstruction of the main retinal vein at or posterior to the optic nerve head,[3] it affects both men and women, and most commonly occurs in patients who are 60 years of age or older.[2, 4] Although CRVO is usually unilateral,[4] approximately 7.8% of patients with CRVO in one eye also have RVO in the fellow eye.[5] CRVO leads to impaired venous drainage from the eye, which in turn may result in increased venous pressure, reduced arterial perfusion, and retinal ischemia. Retinal non-perfusion leads to an increase in vascular endothelial growth factor (VEGF), which increases vascular permeability, and can cause macular edema, retinal hemorrhage, and neovascularization.[6]

Treatment of macular edema secondary to CRVO involves the administration of anti-VEGF agents, such as aflibercept and ranibizumab, which have become the standard of care. The efficacy and safety of intravitreal aflibercept (IVT-AFL) was assessed in two pivotal Phase 3 studies, COPERNICUS (NCT00943072)[7, 8] and GALILEO (NCT01012973),[9, 10] in which findings demonstrated that IVT-AFL was beneficial for the treatment of macular edema secondary to CRVO. In these studies, the mean change from baseline to Week 24 in best-corrected visual acuity (BCVA) was +17.3 and +18.0 letters for patients treated with IVT-AFL compared with −4.0 and +3.3 letters in patients who received sham injections, respectively.[7, 10] These studies demonstrate how, if left untreated, patients with macular edema secondary to CRVO lose visual acuity (VA) and have a poor prognosis. This was similarly shown in the CRUISE study (NCT00485836), in which mean change from baseline BCVA at Month 6 was +12.7 letters and +14.9 letters in the 0.3 mg and 0.5 mg ranibizumab groups, respectively, and +0.8 letters in the sham group.[11] Both the COPERNICUS and GALILEO studies included *pro re nata* (PRN) dosing from Week 24

of treatment to investigate the possibility of extending the treatment interval beyond 4 weeks. *Post-hoc* assessment of the different dosing subgroups demonstrated some de-stabilization of the disease with PRN dosing. Although the deterioration seen during the study period was minor, possibly due to the regular monitoring schedule implemented in these trials, it is likely to progress over the expected longer-term treatment duration that is required in the real-world setting for patients with macular edema secondary to CRVO.

The LEAVO study (ISRCTN13623634) compared IVT-AFL, bevacizumab, and ranibizumab using a PRN dosing regimen and introduced a threshold of treatment success for suspending treatment (>83 Early Treatment Diabetic Retinopathy Study [ETDRS] letters), which allowed a comparative assessment of the treatment burden associated with each treatment arm.[12] Treatment with any of these three anti-VEGF agents resulted in improved and sustained VA when patients were monitored regularly and treated promptly (IVT-AFL, +15.1 letters; ranibizumab, +12.5 letters; and bevacizumab, +9.8 letters at Week 100). Notably, IVT-AFL was non-inferior to ranibizumab at Week 100.

Post-hoc analyses of COPERNICUS and GALILEO support the implementation of proactive treatment to prevent deterioration of functional and anatomic outcomes. Treat and extend (T&E) is a proactive, individualized dosing strategy, whereby the patient receives an injection at every visit. The treatment interval is decided at every visit and is gradually extended if functional and anatomic stability is maintained, and shortened if deterioration is observed, to minimize the risk of disease recurrence rather than in response to it.[13] Additionally, with T&E dosing regimens, the need for interim monitoring is minimized, which reduces the number of appointments per patient and minimizes the need for monitoring visits.[14] Decreasing the number of visits per patient reduces the treatment burden and the need for scheduling visits, thus benefiting both the patient and the healthcare providers.

To our knowledge, T&E dosing regimens have not been evaluated in large-scale studies of IVT-AFL for the treatment of macular edema secondary to CRVO. The aim of the CENTERA study was therefore to assess the efficacy and safety of IVT-AFL administered in a T&E dosing regimen in patients with macular edema secondary to CRVO.

Methods

Study Design

CENTERA was a 76-week, multicenter, open-label, single-arm, Phase 4 study (ClinicalTrials.gov identifier: NCT02800642) that assessed the efficacy and safety of IVT-AFL administered in a T&E dosing regimen in treatment-naive patients with macular edema secondary to CRVO. CENTERA was conducted between June 2016 and July 2019 at 42 study centers in Australia, Canada, Denmark, France, Germany, Italy, Spain, and the UK, in accordance with the Declaration of Helsinki and the International Council for Harmonisation guideline E6: Good Clinical Practice. The protocol and any amendments were reviewed and approved by each study site's Independent Ethics Committee or Institutional Review Board (IRB) before the start of the study. The name of each study site's IRB is listed in **Supplemental Table 1.** All enrolled patients provided written informed consent.

Participants

Treatment-naive patients ≥18 years of age with center-involved macular edema secondary to CRVO for no longer than 3 months were enrolled. Patients were required to have a BCVA of 73-24 ETDRS letters (Snellen equivalent of 20/40 to 20/320) in the study eye. All patients were scheduled to be treated with IVT-AFL as part of routine clinical practice, with the intent to use a T&E regimen after initial dosing. Exclusion criteria are listed in the **Supplementary material**.

Interventions

CENTERA was a single-arm study and patients received treatment at the discretion of the physician. All patients received 2 mg IVT-AFL injections at baseline and every 4 weeks until disease stability criteria were met, or until Week 20, whichever occurred first (the initiation

phase of the treatment). Starting at Week 8, the re-treatment interval was determined, and the frequency of injections could be adjusted by 2-week increments, to maintain stable functional and anatomic outcomes (the T&E phase of treatment).

The stability criteria were: no new cysts found on optical coherence tomography; BCVA within a ±5 letter "stability corridor" (defined as no more than a 5-letter gain since the last or second to last visit and no more than a 5-letter loss from best previous BCVA at any visit); and central retinal thickness (CRT) within a ±20% "stability corridor" (defined as no more than 20% thickness reduction since the last or second to last visit and no more than 20% thickening from best previous CRT at any visit). Values of BCVA and CRT outside of these "stability corridors" were considered to be "improvements" for higher BCVA values and lower CRT values, and "deteriorations" for lower BCVA values and higher CRT values.

From Week 8, at every treatment visit (and at Weeks 24, 52, and 76), the physician determined the stability status of each patient, and the following algorithm was used to determine the re-treatment interval: if the condition was stable (all stability criteria met), the treatment interval was extended by 2 weeks; if the condition was improving (no new cysts and improvement in at least one of the disease activity criteria [BCVA or CRT] with the other improving or stable), the treatment interval was maintained; and if the condition was deteriorating (new cysts and/or deterioration in at least one of the other disease activity criteria [BCVA or CRT]), the treatment interval was reduced by 2 weeks. Injections were not to be administered more frequently than every 4 weeks (minimum re-treatment interval).

Study Endpoints

The pre-determined co-primary endpoints were the proportion of patients who gained ≥15 letters from baseline to Week 76 and the proportion of patients with a mean treatment interval of ≥8 weeks from the last initiation phase visit to Week 76. These endpoints were

met if significantly ≥40% of patients gained ≥15 letters and if significantly ≥50% of patients had a mean treatment interval of ≥8 weeks.

Secondary endpoints included mean change in BCVA and CRT from baseline to Weeks 24, 52, and 76, the number of injections from baseline to Week 76, and the mean treatment interval from baseline to Week 76. Other endpoints reported included the proportion of patients who lost <15 letters. The following *post-hoc* analyses were also conducted: the proportion of patients who achieved a last actual (defined as the length of the interval before study end [last]) and last intended treatment interval (defined as the next planned interval [next planned]) of ≥8 weeks and the proportion of patients who had a BCVA of ≥70 letters at all mandatory study visits. Safety was assessed throughout the study period. Adverse events (AEs) were treatment-emergent if they occurred or worsened after the first IVT-AFL dose and, at most, 30 days after the last dose. All AEs were reported in case-report forms and coded using Medical Dictionary for Regulatory Activities, version 22.0. An adjudication of AEs according to the Antiplatelet Trialists' Collaboration (APTC) criteria was also performed.

Statistical Analysis

Study success required that a gain of ≥15 letters at Week 76 was reached by significantly more than 40% of patients and that a mean treatment interval of ≥8 weeks was reached by significantly more than 50% of patients during the T&E phase. The exact one-sample binomial test was used to assess each of the co-primary efficacy variables at a significance level of 5% (two-sided test) using the full analysis set (FAS), and 95% confidence intervals (CIs) were provided. A sample size of 150 patients was calculated to provide a power of ≥90% to meet both co-primary endpoints, assuming a true probability for gaining ≥15 letters of 55% and a true probability to reach a mean treatment interval of ≥8 weeks of 65%. All

other variables were analyzed by descriptive statistical methods, and frequency tables were generated for categorical data.

The safety analysis set included all enrolled patients who received IVT-AFL. The FAS included all enrolled patients who received IVT-AFL, had a baseline BCVA assessment, and had at least one post-baseline BCVA assessment. The primary efficacy analysis was conducted using the FAS. The per-protocol set (PPS) included all enrolled patients who received IVT-AFL, had a BCVA assessment at study baseline, had at least one BCVA assessment at Week 24 or later, and did not have a major protocol deviation. The co-primary efficacy variable sensitivity analysis was conducted on the PPS.

Statistical evaluation was performed using Statistical Analysis System, v9.4 (SAS Institute Inc., Cary, NC, USA).

Results

Patients

Of the 244 patients who were enrolled, 162 completed screening and entered the treatment period. Two patients had no post-baseline assessments available and were not included in the FAS. Overall, 92.6% (n=150) of patients completed the study. The reasons for study discontinuation were death (n=4), withdrawal by patient (n=3), AEs (n=2), physician decision (n=2), and lost to follow-up (n=1). In total, 147 patients were included in the PPS (**Figure 1**).

The overall mean (standard deviation [SD]) age was 66.2 (13.4) years, and 60.0% of patients were male (**Table 1**). At baseline, mean (SD) BCVA was 51.9 (16.9) letters and mean (SD) CRT was 759.9 (246.0) µm.

Treatment Exposure

Patients received a mean (SD) of 5.3 (0.7) (baseline to Week 24), 3.9 (1.3) (Weeks 24–52), and 3.0 (1.3) (Weeks 52–76) IVT-AFL injections. Of those who completed treatment (n=150), the mean treatment interval in the T&E phase was 7.6 (1.9) weeks, and the mean length of the last and next planned treatment interval was 9.3 (3.5) weeks and 9.7 (3.8) weeks, respectively. Overall, 25.6% (n=41) and 36.9% (n=59) of patients achieved a last and a next planned treatment interval of ≥12 weeks, respectively.

Efficacy

In total, 65.6% (n=105; 95% CI, 57.7–72.9, *P* <0.0001 [test against threshold of 40%]) of patients gained ≥15 letters from baseline to Week 76. Overall, 45.0% (n=72; 95% CI, 37.1–53.1, *P* = 0.8822 [test against threshold of 50%]) of patients achieved a mean treatment interval of ≥8 weeks during the T&E phase. Additionally, 63.1% (n=101) of patients achieved a last and 67.5% (n=108) a next planned treatment interval of ≥8 weeks.

A sensitivity analysis of the co-primary efficacy variables conducted on the PPS provided similar results to the primary analysis on the FAS: 66.7% (n=98; 95% CI, 58.4–74.2) of patients gained ≥15 letters from baseline to Week 76 and 47.6% (n=70; 95% CI, 39.3–56.0) of patients achieved a mean treatment interval of ≥8 weeks during the T&E phase.

Clinically meaningful improvements in mean BCVA were observed at all mandatory visits. Mean (SD) BCVA was 51.9 (16.8) letters at baseline and 72.3 (18.5) letters at Week 76 (mean change: +20.3 [19.5] letters) (**Figure 2**).

Overall, 70.0 % (n=112) of patients gained ≥15 letters and 95.6% (n=153) of patients maintained vision (<15 letters loss) from baseline to Week 76 in the FAS (last observation carried forward [LOCF]). Categorical BCVA gains and losses from baseline to Week 76 are shown in **Supplemental Figure 1**.

In a *post-hoc* analysis of the FAS, 13.8% (n=22) of patients had a baseline BCVA of ≥70 letters (20/40 Snellen equivalent), which increased to 66.9% (n=107) of patients at Week 76 (LOCF). Overall, 60.0% (n=96) of patients included in the FAS had a BCVA of ≥70 letters at all mandatory study visits (Weeks 24, 52, and 76).

Clinically meaningful improvements in mean CRT were observed at all mandatory visits. Mean (SD) CRT decreased from 759.9 (246.0) µm at baseline to 265.4 (57.9) µm at Week 76 (mean change: −496.1 [252.4] µm) (**Figure 3**).

Safety

In total, 80.9% (n=131) of patients reported at least one treatment-emergent AE (TEAE) during the study, and these were predominantly mild or moderate in severity (**Table 2**). Overall, 55.6% (n=90) of patients reported ocular TEAEs in the study eye, the most common of which were reduced VA (14.8% [n=24]), increased intraocular pressure (12.3% [n=20]), conjunctival hemorrhage (9.3% [n=15]), and retinal ischemia (9.3% [n=15]). No cases of endophthalmitis were reported. A listing of ocular TEAEs ≥1% in the study eye is reported in **Supplemental Table 2**.

Serious TEAEs were reported in 19.8% (n=32) of patients, and 4.9% (n=8) of patients experienced serious ocular TEAEs in the study eye. One case of intraocular inflammation (IOI), iridocyclitis, and one case of retinal artery occlusion (0.6% each) were assessed as serious TEAEs related to IVT-AFL. In total, there were four deaths reported; one patient had an APTC event (pulmonary embolism; the patient also experienced a lower respiratory tract infection and atrial flutter). The three other deaths reported were due to B-cell lymphoma, intestinal perforation, and pneumonia (n=1 each). Two deaths were treatment-emergent and none were assessed as being related to IVT-AFL.

Discussion

CENTERA was among the first studies to evaluate IVT-AFL administered in a T&E dosing regimen for the treatment of macular edema secondary to CRVO on a relatively large scale.

This study showed that IVT-AFL administered in a T&E dosing regimen improved functional and anatomic outcomes in patients with macular edema secondary to CRVO over 76 weeks. Overall, 66% of patients gained ≥15 letters from baseline to Week 76; conversely, the proportion of patients who achieved a mean treatment interval of ≥8 weeks between the last initiation phase visit and Week 76 did not reach statistical significance. The robustness of these results was further demonstrated in a sensitivity analysis on the PPS.

Although fewer than half of patients achieved a mean treatment interval of ≥8 weeks, *post-hoc* analysis demonstrated that 63% and 68% of patients achieved a last and next planned treatment interval of ≥8 weeks, respectively. Functional and anatomic improvements were achieved with a mean of five injections (baseline to Week 24), four injections (Weeks 24–52), and three injections (Weeks 52–76). As expected with the T&E treatment paradigm, treatment burden was highest during the initiation phase and decreased over time. The downwards trend in the intensity of the treatment pattern through to the end of the study further supports the notion that a mean treatment interval of ≥8 weeks between the last initiation phase visit and Week 76 may have been met with the implementation of a longer observation period.

Clinically meaningful improvements in BCVA were observed at all mandatory study visits, with a mean change from baseline of +20 letters at Week 76. Results of a *post-hoc* analysis showed that, by Week 76, 67% of patients had a BCVA of ≥70 letters, which is a threshold for maintaining a driving license in many countries. Clinically meaningful

improvements in anatomic outcomes were also observed at all mandatory study visits, with a mean change in CRT of −496 µm at Week 76. The majority of the reduction in CRT was seen following the first IVT-AFL injection (−462 µm at Week 4). It is also worth noting that 73% of patients were treated within 4 weeks of diagnosis. The safety profile of IVT-AFL was consistent with previous studies.[8, 9] Notably, there were no cases of endophthalmitis and only one case of IOI.

The functional and anatomic outcomes achieved in CENTERA using a T&E regimen are similar to those seen in other studies of IVT-AFL with monthly or PRN dosing.[8, 9, 12, 15] The mean change in BCVA from baseline to Week 24 was +20 letters in CENTERA, +17 letters in COPERNICUS,[7] +18 letters in GALILEO,[10] +19 letters in SCORE-2,[15] and +13 letters in LEAVO.[12] The mean change in CRT from baseline to Week 52 was −481 µm in CENTERA, −413 µm in COPERNICUS, and −424 µm GALILEO[8, 9].

The majority of patients in the CENTERA study had non-ischemic CRVO (93%). In the COPERNICUS[7] and VIBRANT[16] studies of IVT-AFL, a smaller proportion of patients had non-ischemic disease, 67.5% and 60.4%, respectively. In all three studies, patients showed improvement in functional and anatomic outcomes, therefore indicating that IVT-AFL therapy is effective in patients with both ischemic and non-ischemic CRVO.

The importance of differentiating fluid compartments is gaining increasing attention in neovascular age-related macular degeneration (nAMD), whereby fluid compartments have been shown to have differential effects on functional outcomes[17]. It is feasible that tolerance of anti-VEGF resistant fluid in specific compartments (such as subretinal fluid) may allow extension of intervals while maintaining good functional outcomes. However, the impact of such an approach on the treatment of macular edema secondary to CRVO is yet to be explored. Additionally, possibly more so than in nAMD, the treatment burden in CRVO

significantly lessens over time as the disease appears to stablize more effectively, potentially enabling further extension of treatment intervals as the disease stabilizes.

Further data, including those from the LEAVO study, suggest that a lower treatment intensity may have a detrimental impact on functional outcomes. It is possible that the lower number of injections through 52 weeks in LEAVO compared with CENTERA (approximately 7.0 vs 9.2 injections, respectively) allowed for persistent fluid and more recurrences. Initial monthly dosing for CRVO may need to be more protracted than the typical treatment schedule of three initial monthly doses in nAMD.

Published studies, including LEAVO,[12] have also demonstrated the superior durability of IVT-AFL compared with ranibizumab, as evidenced by the lower mean number of injections over 100 weeks with IVT-AFL (10.0 vs 11.8 injections, respectively). However, the vision gains in LEAVO at 100 weeks (+15 letters for IVT-AFL) were not as high as those reported in CENTERA at 76 weeks (+20 letters), possibly supporting the requirement for proactive treatment (such as T&E) in patients with CRVO.

This study had a number of strengths, including a high statistical power of ≥90%, inclusion of a broad range of baseline visual function (73-24 ETDRS letters; 20/40 to 20/320 Snellen equivalent) and early initiation of treatment. Limitations of this study are that it was a single-arm study with no active comparator, thus potentially limiting the interpretation of the results. However, the single-arm design was chosen to evaluate the utility of the T&E regimen in patients with CRVO, as this regimen has not previously been analysed in large clinical studies within this patient population. Furthermore, the analysis of the last and next planned treatment intervals was *post hoc* in nature, which limited the interpretation of the data.

Overall, clinically meaningful and significant improvements in functional and anatomic outcomes were achieved with IVT-AFL administered using a T&E regimen in

patients with macular edema secondary to CRVO. Treatment intervals were also extended, and the majority of patients achieved a last and next planned treatment interval of ≥8 weeks.

Acknowledgments

a) Funding/Support

This study was sponsored by Bayer AG, Leverkusen, Germany. Medical writing and editorial support for the preparation of this manuscript was funded by Bayer Consumer Care AG, Switzerland. Bayer AG participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

b) Financial Disclosures

J-FK: Consultant for Alcon, Allergan, Bayer, Kanghong, Krys, NanoRetina, Novartis, Novo Nordisk, Roche, Théa, and Zeiss

ML: Served as a study investigator and consultant and the Rigshospitalet has received compensation for clinical trials: AbbVie, Novartis, Bayer, Novo Nordisk, Allergan, GlaxoSmithKline, Spark Therapeutics, Oculis, Biogen, AstraZeneca and Acucela

NE: Consultant for Roche, Bayer, Novartis and Allergan; and grant support from Bayer and Novartis

CB: Attendance at advisory boards/lecture fees for Bayer, Novartis, Alimera Sciences, and Roche

SW: Consultant for Allergan, Bayer, Heidelberg Engineering, Novartis, Optos Inc., Zeiss, and Roche; and grant support from Heidelberg Engineering

TS: Employee of Bayer AG, Berlin, Germany; and stock ownership at Bayer AG, Berlin, Germany

HA: Employee of Bayer Consumer Care AG, Basel, Switzerland

VC: Served as a scientific advisor for Alcon Laboratories, Bayer Healthcare, and Novartis Pharma AG; and received grant support from Allergan Inc., Bayer Healthcare, and Novartis Pharma AG

J-FK, ML, NE, CB, SW, and VC are CENTERA Steering Committee members

c) Other Acknowledgments

The authors thank all the patients and investigators who participated in the study. Medical writing and editorial support for the preparation of this manuscript, under the guidance of

the authors, was provided by ApotheCom, UK, and was funded by Bayer Consumer Care AG, Switzerland.

d) Author Contributions

All authors contributed to the conceptualization of the study design, data curation, investigation, visualization, and provided critical review of the manuscript.

Access to data and data analysis

Availability of the data underlying this publication will be determined according to Bayer's commitment to the EFPIA/PhRMA, "Principles for responsible clinical trial data sharing." This pertains to scope, time point, and process of data access.

As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the United States (US) and European Union (EU) as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 1, 2014.

Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

Data access will be granted to anonymized patient-level data, protocols and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.

CENTERA study investigators

Dr. Josep Callizo

Prof. Gerd Auffarth

Dr. Huesnue Berk

Dr. Maria-Andreea Gamulescu

Dr. Nicole Eter

Prof. Arthur Mueller

Dr. Fanni Molnar

Prof. Dr. Rainer Guthoff

Prof. Matus Rehak

Dr. Amelie Pielen

Prof. Albert Augustin

Dr. Hakan Kaymak

Prof. Ulrich Kellner

Dr. Clare Bailey

Dr. Jignesh Patel

Dr. Faruque Ghanchi

Dr. Ahmed Kamal

Dr. Srilakshmi Sharma

Dr. Maged Habib

Prof. Jean-François Korobelnik

Prof. Catherine Creuzot-Garcher

Prof. Laurent Kodjikian

Prof. Federico Ricci

Prof. Cesare Mariotti

Prof. Francesco Bandello

Dr. Monica Varano

Prof. Edoardo Midena

Prof. Giovanni Staurenghi

Prof. Marco Nardi

Dr. Isaac Alarcón Valero

Dr. Jose-Juan Escobar Barranco

Dr. Álvaro Fernandez-Vega Sanz

Dr. Laura Sararols Ramsay

Dr. Monica Asencio Duran

Dr. Catalina Esmerado Appiani

Dr. Laurent Lalonde

Dr. John Gonder

Dr. Michel Giunta

Dr. Varun Chaudhary

Dr. Michael Fielden

Dr. Serge Bourgault

Dr. Karim Hammamji

Prof. Michael Larsen

Prof. Henrik Vorum

Dr. Jennifer Arnold

Dr. Andrew Chang

Dr. Alan Luckie

Prior presentation

EURETINA 2020 Virtual Congress, 2–4 October

REFERENCES

1. Baseline and early natural history report. The Central Vein Occlusion Study. *Arch Ophthalmol* 1993;111(8):1087-95.
2. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the Management of Retinal Vein Occlusion by the European Society of Retina Specialists (EURETINA). *Ophthalmologica* 2019;242(3):123-162.
3. Pulido JS, Flaxel CJ, Adelman RA, Hyman L, Folk JC, Olsen TW. Retinal Vein Occlusions Preferred Practice Pattern(®) Guidelines. *Ophthalmology* 2016;123(1):P182-208.
4. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. *Trans Am Ophthalmol Soc* 2000;98133-41; discussion 141-3.
5. Leitner D, Thomas A, Fekrat S. Bilateral Retinal Vein Occlusion. *Invest Ophthalmol Vis Sci* 2017;58(8):1548-1548.
6. Noma H, Funatsu H, Mimura T, Harino S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion. *Ophthalmology* 2009;116(1):87-93.
7. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. *Ophthalmology* 2012;119(5):1024-32.
8. Brown DM, Heier JS, Clark WL, et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study. *Am J Ophthalmol* 2013;155(3):429-437.e7.
9. Korobelnik JF, Holz FG, Roider J, et al. Intravitreal aflibercept injection for macular edema resulting from central retinal vein occlusion: One-year results of the Phase 3 GALILEO study. *Ophthalmology* 2014;121(1):202-208.
10. Holz FG, Roider J, Ogura Y, et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. *Br J Ophthalmol* 2013;97(3):278-84.
11. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology* 2010;117(6):1124-1133.e1.
12. Hykin P, Prevost AT, Vasconcelos JC, et al. Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial. *JAMA Ophthalmol* 2019;137(11):1256-1264.
13. Freund KB, Korobelnik JF, Devenyi R, et al. Treat-and-extend regimens with anti-VEGF agents in retinal diseases: A literature review and consensus recommendations. *Retina* 2015;35(8):1489-506.
14. Lanzetta P, Loewenstein A, Vision Academy Steering Committee. Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases. *Graefes Arch Clin Exp Ophthalmol* 2017;255(7):1259-1273.
15. Scott IU, VanVeldhuisen PC, Ip MS, et al. Effect of Bevacizumab vs Aflibercept on Visual Acuity Among Patients With Macular Edema Due to Central Retinal Vein Occlusion: The SCORE2 Randomized Clinical Trial. *JAMA* 2017;317(20):2072-2087.
16. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. *Ophthalmology* 2015;122(3):538-544.
17. Jaffe GJ, Ying GS, Toth CA, et al. Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials. *Ophthalmology* 2019;126(2):252-260.

Figure captions

FIGURE 1. Patient disposition. [a]Two patients had no post-baseline assessments available and were included in the full analysis set.

AE = adverse event; IVT-AFL = intravitreal aflibercept.



FIGURE 2. Mean change in BCVA from baseline to Week 76. Full analysis set; last observation carried forward. Error bars are 95% confidence intervals. BCVA = best-corrected visual acuity; ETDRS = Early Treatment Diabetic Retinopathy Study; IVT-AF = intravitreal aflibercept; SD = standard deviation.



FIGURE 3. Mean change in CRT from baseline to Week 76. Full analysis set; last observation carried forward. Error bars are 95% confidence intervals. Change at Week 4, n=156; Week 8, n=157; and Weeks 24, 52, and 72, n=158. CRT = central retinal thickness; IVT-AFL = intravitreal aflibercept; SD = standard deviation.



	n	Mean absolute CRT (SD)
Baseline	158	759.9 (246.0)
Week 4	158	300.4 (46.4)
Week 8	159	281.2 (53.8)
Week 24	160	271.2 (53.1)
Week 52	160	279.8 (106.8)
Week 76	160	265.4 (57.9)

TABLE 1. Patient Baseline Demographics and Disease Characteristics

Characteristic	IVT-AFL N=160
Mean age, years (SD)	66.2 (13.4)
Age range, years, n (%)	
18–64	62 (38.8)
65–84	87 (54.4)
≥85	11 (6.9)
Sex, n (%)	
Male	96 (60.0)
Race, n (%)	
White	152 (95.0)
Asian	3 (1.9)
Black	1 (0.6)
Not reported	4 (2.5)
Mean BVCA ETDRS letters, (SD)	51.9 (16.9)
Mean CRT, µm (SD)[a]	759.9 (246.0)
Weeks since CRVO diagnosis, n (%)[b]	
0	3 (1.9)
1	35 (22.3)
2	43 (27.4)
3	21 (13.4)
4	13 (8.3)
5	8 (5.1)
6	9 (5.7)
7	5 (3.2)
8	3 (1.9)
9	3 (1.9)
≥10	17 (10.8)
Mean refraction sphere, diopters (SD)	1.8 (1.7)
Capillary non-perfusion on FA, n (%)	
No	149 (93.1)
Yes	11 (6.9)
Location of capillary non-perfusion on FA, n (%)	
Q1, Q2, Q3, Q4	6 (3.8)
Q2, Q3	3 (1.9)
Q3	2 (1.3)
Gonioscopy, n (%)	
Normal	148 (92.5)
Abnormal	9 (5.6)
Missing	3 (1.9)

[a]n=158; [b]n=157. Full analysis set. BVCA = best-corrected visual acuity; CRT = central retinal thickness; CRVO = central retinal vein occlusion; ETDRS = Early Treatment Diabetic Retinopathy Study; FA = fluorescein angiography; IVT-AF = intravitreal aflibercept; Q = quadrant; SD = standard deviation.

TABLE 2. Safety Overview at Week 76

Number of patients (%)	IVT-AFL N=162
Any AE	134 (82.7)
Any ocular AE	103 (63.6)
Any TEAE	131 (80.9)
Any ocular TEAE	98 (60.5)
Any ocular TEAE in the study eye	90 (55.6)
Any ocular TEAE in the fellow eye	56 (34.6)
Any non-ocular TEAE	106 (65.4)
Any TEAE related to study drug	6 (3.7)
Any TEAE related to IVT injection procedure	48 (29.6)
Any TEAE related to other procedures required by the protocol	10 (6.2)
Maximum intensity for any TEAE	
Mild	41 (25.3)
Moderate	70 (43.2)
Severe	20 (12.3)
Ocular TEAEs in the study eye ≥5%	
Visual acuity reduced	24 (14.8)
Increased intraocular pressure	20 (12.3)
Conjunctival hemorrhage	15 (9.3)
Retinal ischemia	15 (9.3)
Macular edema	10 (6.2)
Foreign body sensation	9 (5.6)
Retinal hemorrhage	9 (5.6)
Vitreous detachment	9 (5.6)
Any SAE	37 (22.8)
Any treatment-emergent SAE	32 (19.8)
Any treatment-emergent SAE related to study drug[a]	2 (1.2)
Any treatment-emergent SAE related to IVT injection procedure[a]	2 (1.2)
Any treatment-emergent SAE causally related to other procedures required by the protocol	0
Discontinuation of study drug due to AEs	6 (3.7)
Discontinuation of study drug due to TEAEs	2 (1.2)
Any APTC event	1 (0.6)
Any deaths	4 (2.5)
Any treatment-emergent deaths	2 (1.2)

[a]Both cases were related to study drug and IVT injection procedure. Safety analysis set. AE = adverse event; APTC = Anti-Platelet Trialists' Collaboration; IVT = intravitreal; IVT-AFL = intravitreal aflibercept; SAE = serious adverse event; TEAE = treatment-emergent adverse

event.

Table of Contents Statement

CENTERA evaluates the efficacy and safety of intravitreal aflibercept treat-and-extend dosing in patients with macular edema secondary to central retinal vein occlusion. Overall, clinically meaningful improvements in functional and anatomic outcomes were achieved. Treatment intervals were extended, and the majority of patients achieved last and next planned treatment intervals of ≥8-weeks. These results support the use of intravitreal aflibercept treat-and-extend dosing in patients with macular edema in central retinal vein occlusion within clinical practice.